Member Info for CHELSEA7

Interesting part-------------Of the 1,120 therapies in the clinic, nearly 300 are immuno-oncology drugs or vaccines. And just what counts as immuno-oncology? The organization said it counted �recognized classes� such as CAR-T therapies, bi-specific antibodies, cytokine therapies, immune checkpoint modulators, oncolytic virus therapies, and vaccines.

Lets hope so. Have a good break. Take care

http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

Cancer drugs are crowding in to an already cramped pipeline this year, with hundreds of immuno-oncology hopefuls now taking a shot at clinical testing. That�s according to a new cancer report from PhRMA, which counted 1,120 oncology drugs in the clinic so far this year � a massive increase from previous years � and that�s just in the US. For perspective, there were only 836 cancer therapies counted by PhRMA in 2015, which means the pipeline has swelled 34% in less than three years. The organization only counted drugs already in the clinic or awaiting review from the FDA. That means there�s a significant backlog of therapies in preclinical development, waiting to elbow their way into the fray. Of the 1,120 therapies in the clinic, nearly 300 are immuno-oncology drugs or vaccines. And just what counts as immuno-oncology? The organization said it counted �recognized classes� such as CAR-T therapies, bi-specific antibodies, cytokine therapies, immune checkpoint modulators, oncolytic virus therapies, and vaccines. SOURCE: PhRMA The report takes a regional look at a trend we�ve been tracking for a while now. Back in January, an Endpoints News�panel discussed the rapid expansion of the oncology pipeline (in particular, immuno-oncology) at the JP Morgan Healthcare Conference in San Francisco. That report identified a mind-boggling 2,004 immuno-oncology agents, with 940 in the clinic and the rest in preclinical development. There�s been an ongoing discussion about whether the market can support the crowding in fields such as PD-1/L1 � not just in the US, but in China and other regions. For its part, PhRMA remains upbeat about the pipeline, touting the industry�s innovations and calling attention to the 85% of cancer drugs in development it says are first-in-class treatments. And the organization is quick to point out that the need for new cancer treatments is still crucial. Although cancer death rate has declined 26% since its peak in the 1990s, more than 1.7 million new cases of cancer are expected to develop in the US in 2018. For a complete list of the 1,120 cancer drugs in development, check out PhRMA�s new list.

13/13.50

In the context of the conversation, yes.

Bermuda, well it wasn"t my choice of words.

But they do now, lol.

No. But they had never heard of Juno and Kite either!! They are so wrapped up in the "now" IMHO

I even mentioned last year that maybe it is better starting our SCIB1 Combo Trial later once a few earlier trials are finished.

Exactly what was said, in respect of early trials.

Bermuda, we had this conversation a couple of years ago when i said they are focussing on there own pipelines. You actually replied with something similar then.

And , in four years of conversations with my oncologist, believe me there were many conversations!! He said all those years ago the Pharmas will be driven by greed, but we know that, they are a business.

That is true, but, the indications they fought for were rarely inany areas where they had monothereapy approval. My opinion based on my research at the time.

Wildforce, you will find the earliest combos are pharma combining their own pipelines. Said this often. Not for patients benefit.

Thanks Wild, something we have discussed often. https://www.ft.com/content/d39afa5e-6066-11e8-9334-2218e7146b04

Well thats why i think they had to submit it before Scancell. Every trial needs same procedure.? Konar knows his stuff though be happy to be corrected.

Likewise, would have thought they still have to submit IND for any other trial though.

Konar is that relevant to the SCIB1 trial??

Thought so, lol. Night